906559-46-4

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 4-(4-Boc-1-piperazinyl)-3-chlorobenzoate is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the modification of biological activity and pharmacokinetic properties of the final drug products.
Used in Agrochemical Industry:
In the agrochemical sector, Methyl 4-(4-Boc-1-piperazinyl)-3-chlorobenzoate is utilized as a precursor in the development of agrochemicals, leveraging its chemical structure to enhance the effectiveness of these compounds in agricultural applications.
Used in Medicinal Chemistry Research:
Methyl 4-(4-Boc-1-piperazinyl)-3-chlorobenzoate serves as a valuable compound in medicinal chemistry research, where it is employed to explore new drug candidates and understand the structure-activity relationships of potential therapeutic agents.
Used in Drug Development:
Methyl 4-(4-Boc-1-piperazinyl)-3-chlorobenzoate is also used in drug development processes, where its unique structural features allow for the creation of new molecular entities with improved therapeutic profiles, including enhanced efficacy, selectivity, and safety.

Upstream product

• 234082-35-0 methyl 3-chloro-4-fluorobenzoate 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 403-16-7 3-chloro-4-fluorobenzoic acid 

Downstream Products

• 1236119-57-5 3-chloro-N-methyl-4-(piperazin-1-yl)benzamide 

Relevant academic research and scientific papers

POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS

The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of poly(ADP-ribose)polymerase (PARP). The definitions of the variables are provided herein.

Mechanisms of action of novel influenza A/M2 viroporin inhibitors derived from hexamethylene amiloride

The increasing prevalence of influenza viruses with resistance to approved antivirals highlights the need for new anti-influenza therapeutics. Here we describe the functional properties of hexamethylene amiloride (HMA)'derived compounds that inhibit the wildtype and adamantane-resistant forms of the influenza A M2 ion channel. For example, 6-(azepan-1-yl)-N-carbamimidoylnicotinamide (9) inhibits amantadine-sensitive M2 currents with 3- to 6-fold greater potency than amantadine or HMA (IC50 5 0.2 vs. 0.6 and 1.3 μM, respectively). Compound 9 competes with amantadine for M2 inhibition, and molecular docking simulations suggest that 9 binds at site(s) that overlap with amantadine binding. In addition, tert-butyl 4′-(carbamimidoylcarbamoyl)-2′,3-dinitro- [1,1′-biphenyl]-4-carboxylate (27) acts both on adamantanesensitive and a resistantM2variant encoding a serine to asparagine 31 mutation (S31N) with improved efficacy over amantadine and HMA (IC5050.6 μMand4.4mM, respectively).Whereas 9 inhibited in vitro replication of influenza virus encoding wild-type M2 (EC505 2.3 μM), both 27 and tert-butyl 4′-(carbamimidoylcarbamoyl)-2′,3- dinitro-[1,1′-biphenyl]-4-carboxylate (26) preferentially inhibited viruses encoding M2(S31N) (respective EC50 5 18.0 and 1.5 μM). This finding indicates thatHMAderivatives can be designed to inhibit viruses with resistance to amantadine. Our study highlights the potential of HMA derivatives as inhibitors of drug-resistant influenza M2 ion channels.

PYRIDYL AND PHENYL SUBSTITUTED PIPERAZINE-PIPERIDINES WITH CXCR3 ANTAGONIST ACTIVITY

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non limiting example(s) include, psoriasis), autoimmune diseases (non limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g , tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.